SciClone Pharmaceuticals (SCLN) : Stonepine Capital Management reduced its stake in SciClone Pharmaceuticals by 47.16% during the most recent quarter end. The investment management company now holds a total of 1,082,532 shares of SciClone Pharmaceuticals which is valued at $11,269,158 after selling 966,106 shares in SciClone Pharmaceuticals , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.SciClone Pharmaceuticals makes up approximately 12.03% of Stonepine Capital Management’s portfolio.
Other Hedge Funds, Including , Pinebridge Investments added SCLN to its portfolio by purchasing 6,329 company shares during the most recent quarter which is valued at $65,885.Glenmede Trust Co Na reduced its stake in SCLN by selling 107,093 shares or 25.98% in the most recent quarter. The Hedge Fund company now holds 305,073 shares of SCLN which is valued at $3,200,216. SciClone Pharmaceuticals makes up approx 0.02% of Glenmede Trust Co Na’s portfolio.Strs Ohio reduced its stake in SCLN by selling 13,700 shares or 19.32% in the most recent quarter. The Hedge Fund company now holds 57,200 shares of SCLN which is valued at $601,172. Ls Investment Advisors added SCLN to its portfolio by purchasing 1,965 company shares during the most recent quarter which is valued at $20,240.
SciClone Pharmaceuticals closed down -0.14 points or -1.36% at $10.16 with 13,77,407 shares getting traded on Friday. Post opening the session at $10.18, the shares hit an intraday low of $9.85 and an intraday high of $10.22 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, SciClone Pharmaceuticals reported $0.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.14 according to the earnings call on Nov 9, 2015. Analyst had a consensus of $0.12. The company had revenue of $42.90 million for the quarter, compared to analysts expectations of $40.61 million. The company’s revenue was up 25.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS.
SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments including China and the rest of the world (the United States and Hong Kong). The Company’s lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications and RapidFilm an oral film formulation of ondansetron to treat nausea induced by chemotherapy.